BG103334A - Antiviral vectors - Google Patents
Antiviral vectorsInfo
- Publication number
- BG103334A BG103334A BG103334A BG10333499A BG103334A BG 103334 A BG103334 A BG 103334A BG 103334 A BG103334 A BG 103334A BG 10333499 A BG10333499 A BG 10333499A BG 103334 A BG103334 A BG 103334A
- Authority
- BG
- Bulgaria
- Prior art keywords
- vector particles
- antiviral
- vectors
- antiviral vectors
- consitructed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mushroom Cultivation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9621680.9A GB9621680D0 (en) | 1996-10-17 | 1996-10-17 | Lentiviral vectors |
| PCT/GB1997/002858 WO1998017816A1 (en) | 1996-10-17 | 1997-10-17 | Lentiviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG103334A true BG103334A (en) | 2000-06-30 |
Family
ID=10801598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG103334A BG103334A (en) | 1996-10-17 | 1999-04-14 | Antiviral vectors |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6235522B1 (hu) |
| EP (1) | EP0939827B1 (hu) |
| JP (1) | JP2001502903A (hu) |
| KR (1) | KR20000049250A (hu) |
| CN (1) | CN1195864C (hu) |
| AT (1) | ATE520783T1 (hu) |
| AU (1) | AU737801B2 (hu) |
| BG (1) | BG103334A (hu) |
| CA (1) | CA2268271A1 (hu) |
| CZ (1) | CZ137299A3 (hu) |
| GB (2) | GB9621680D0 (hu) |
| HK (1) | HK1018481A1 (hu) |
| HU (1) | HUP0000442A3 (hu) |
| IL (1) | IL128564A0 (hu) |
| NO (1) | NO991742L (hu) |
| NZ (1) | NZ334522A (hu) |
| PL (1) | PL332876A1 (hu) |
| WO (1) | WO1998017816A1 (hu) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924123B2 (en) * | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| US6277633B1 (en) | 1997-05-13 | 2001-08-21 | The University Of North Carolina At Chapel Hill | Lentivirus-based gene transfer vectors |
| FI112580B (fi) | 1997-06-27 | 2003-12-15 | Nokia Corp | Kutsunsiirron reititys peruspalvelukohtaisesti |
| JP2001517433A (ja) | 1997-09-24 | 2001-10-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 非霊長類レンチウイルスベクターおよびパッケージングシステム |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| EP1088086A4 (en) | 1998-06-24 | 2003-01-08 | Musc Found For Res Dev | RIBOZYMES SPECIFIC TO TISSUE AND TARGET RNA |
| US6958226B1 (en) | 1998-09-11 | 2005-10-25 | The Children's Medical Center Corp. | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| ATE528406T1 (de) | 1999-04-29 | 2011-10-15 | Gbp Ip Llc | Verfahren und mittel zur herstellung von sicheren,rekombinanten lentivirusvektoren mit hohem titer |
| EP1083230A1 (en) * | 1999-09-10 | 2001-03-14 | Academisch Medisch Centrum Amsterdam | Viral replicons and viruses dependent on inducing agents |
| JP2003512829A (ja) | 1999-10-22 | 2003-04-08 | アヴェンティス パストゥール リミテッド | 改変型ｇｐ１００およびその使用 |
| US6656706B2 (en) | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
| EP1702983A3 (en) | 2000-04-13 | 2007-01-10 | Medical University of South Carolina | Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof |
| EP1741782B1 (en) | 2000-05-10 | 2011-06-22 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
| AU2001263160A1 (en) | 2000-05-19 | 2001-12-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Utilization of non-viral sequences for minus-strand dna transfer and gene reconstitution |
| EP1326991A2 (en) * | 2000-10-20 | 2003-07-16 | Whitehead Institute For Biomedical Research | Expression vectors and uses thereof |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| US6712612B1 (en) | 2000-12-12 | 2004-03-30 | Genecure Llc | Safe and stable retroviral helper cell line and related compositions and methods |
| US20040235169A1 (en) * | 2001-04-20 | 2004-11-25 | Evans Ronald M. | Inducible expression of transfected genes |
| WO2002087341A1 (en) * | 2001-05-01 | 2002-11-07 | Genetix Pharmaceuticals, Inc. | Novel self-inactivating (sin) lentiviral vectors |
| EP1412493B1 (en) | 2001-08-02 | 2011-10-05 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
| KR20040054699A (ko) | 2001-10-02 | 2004-06-25 | 엥스띠뛰 끌레이톤 드 라 러쉐르쉬 | 제한된 발현의 렌티바이러스 벡터 및 이의 적용과 관련된방법 및 조성물 |
| SI1504108T1 (sl) | 2002-02-01 | 2013-07-31 | Oxford Biomedica (Uk) Limited | Lentiviralni vektor |
| PT1496939E (pt) | 2002-04-09 | 2007-11-22 | Sanofi Pasteur Ltd | ''ácido nucleico de cea modificado e vectores de expressão'' |
| WO2005035773A2 (en) * | 2003-10-08 | 2005-04-21 | Sanofi Pasteur, Inc. | Modified cea /b7 vector |
| ES2326217T3 (es) * | 2002-04-26 | 2009-10-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Glicoproteinas quimericas mejoradas y vectores lentivirales pseudotipados. |
| CN1759182A (zh) * | 2002-11-22 | 2006-04-12 | 克雷顿研究院 | 调节基因的组合物和系统 |
| WO2005030927A2 (en) * | 2003-09-23 | 2005-04-07 | Uab Research Foundation | Methods and compositions for in vivo inflammation monitoring |
| WO2005118809A2 (en) * | 2004-04-29 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Methods and compositions for enhancing cell adhesion properties |
| US20060292159A1 (en) * | 2005-06-08 | 2006-12-28 | Ranscht Barbara E | Methods for the inhibition of neovascularization and cancer metastasis |
| GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
| WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
| KR101554678B1 (ko) | 2012-10-19 | 2015-09-21 | 영남대학교 산학협력단 | 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도 |
| DK2956477T4 (da) | 2013-02-15 | 2024-04-15 | Bioverativ Therapeutics Inc | Optimeret faktor viii-gen |
| US20160060652A1 (en) * | 2013-03-13 | 2016-03-03 | Lapian's Corp | Microvesicle and method for producing the same |
| WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
| EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
| US11753461B2 (en) | 2016-02-01 | 2023-09-12 | Bioverativ Therapeutics Inc. | Optimized factor VIII genes |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| KR102638884B1 (ko) | 2016-10-12 | 2024-02-22 | 바이오버라티브 유에스에이 인코포레이티드 | 항-C1s 항체 및 그의 사용 방법 |
| JP7045724B2 (ja) | 2016-11-07 | 2022-04-01 | ニューラクル サイエンス カンパニー リミテッド | 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途 |
| US11560425B2 (en) | 2017-06-27 | 2023-01-24 | Neuracle Science Co., Ltd. | Use of anti-FAM19A5 antibodies for treating cancers |
| KR102511122B1 (ko) | 2017-06-27 | 2023-03-22 | 주식회사 뉴라클사이언스 | 녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도 |
| EP3645039A4 (en) | 2017-06-27 | 2021-05-05 | Neuracle Science Co., Ltd | USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS |
| US11618783B2 (en) | 2017-06-27 | 2023-04-04 | Neuracle Science Co., Ltd. | Anti-FAM19A5 antibodies and uses thereof |
| WO2019009979A1 (en) | 2017-07-06 | 2019-01-10 | The Medical College Of Wisconsin, Inc. | NEW IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING CSH-DERIVED LYMPHOCYTES TRANSDUCED BY A VECTOR FOR DISEASE THERAPY |
| TWI823868B (zh) | 2017-10-11 | 2023-12-01 | 美商生物維瑞提夫美國公司 | 誘導補體活性之方法 |
| TW201946929A (zh) | 2018-02-01 | 2019-12-16 | 美商生物化學醫療公司 | 表現因子ｖｉｉｉ之慢病毒載體之使用 |
| CN112424223A (zh) | 2018-04-24 | 2021-02-26 | 纽洛可科学有限公司 | 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途 |
| AU2019265888A1 (en) | 2018-05-10 | 2020-11-26 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof |
| MX2020013923A (es) | 2018-06-29 | 2021-03-29 | Apitbio Inc | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. |
| EP3880231A1 (en) | 2018-11-16 | 2021-09-22 | NeoImmuneTech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
| MX2021006648A (es) | 2018-12-06 | 2021-07-07 | Bioverativ Therapeutics Inc | Uso de vectores lentivirales que expresan el factor ix. |
| KR20200071198A (ko) | 2018-12-10 | 2020-06-19 | 네오이뮨텍, 인코퍼레이티드 | Nrf2 발현 조절 기반 T 세포 항암면역치료법 |
| AU2018454784A1 (en) * | 2018-12-25 | 2021-08-05 | National Center Of Neurology And Psychiatry | Method for inducing muscular cells using cells in spot urine |
| TW202126284A (zh) | 2019-09-30 | 2021-07-16 | 美商百歐維拉提夫治療公司 | 慢病毒載體配製物 |
| AU2021207586A1 (en) | 2020-01-13 | 2022-07-21 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody |
| EP4093752A2 (en) | 2020-01-22 | 2022-11-30 | Outpace Bio, Inc. | Chimeric polypeptides |
| WO2021151001A1 (en) | 2020-01-22 | 2021-07-29 | Outpace Bio, Inc. | Chimeric polypeptides |
| AU2021217373A1 (en) | 2020-02-05 | 2022-08-04 | Neoimmunetech, Inc. | Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells |
| MX2023000156A (es) | 2020-06-24 | 2023-02-16 | Bioverativ Therapeutics Inc | Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina. |
| WO2022087453A1 (en) | 2020-10-22 | 2022-04-28 | Lyell Immunopharma, Inc. | Chimeric activation receptors |
| US20230398184A1 (en) | 2020-10-26 | 2023-12-14 | Neoimmunetech, Inc. | Methods of inducing stem cell mobilization |
| US20240101629A1 (en) | 2020-11-02 | 2024-03-28 | Neoimmunetech, Inc. | Use of interleukin-7 for the treatment of coronavirus |
| JP2023549112A (ja) | 2020-11-05 | 2023-11-22 | ネオイミューンテック， インコーポレイテッド | Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法 |
| WO2022251644A1 (en) | 2021-05-28 | 2022-12-01 | Lyell Immunopharma, Inc. | Nr4a3-deficient immune cells and uses thereof |
| CA3177712A1 (en) | 2021-06-02 | 2022-12-02 | Lyell Immunopharma, Inc. | Nr4a-deficient cells expressing c-jun and uses thereof |
| JP2024537797A (ja) | 2021-09-30 | 2024-10-16 | バイオベラティブ セラピューティクス インコーポレイテッド | 低下した免疫原性を有する第ｖｉｉｉ因子ポリペプチドをコードする核酸 |
| CA3237696A1 (en) | 2021-11-08 | 2023-05-11 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| EP4456907A1 (en) | 2021-12-30 | 2024-11-06 | NeoImmuneTech, Inc. | Method of treating a tumor with a combination of il-7 protein and vegf antagonist |
| WO2024026490A1 (en) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Polynucleotides encoding linked antigens and uses thereof |
| WO2024102722A1 (en) | 2022-11-07 | 2024-05-16 | Neoimmunetech, Inc. | Methods of treating a tumor with an unmethylated mgmt promoter |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604114A (en) * | 1986-05-20 | 1997-02-18 | Dana-Farber Cancer Institute | Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use |
| CA2109579A1 (en) | 1991-05-29 | 1992-12-10 | Julianna Lisziewicz | Eukaryotic expression vectors with regulation of rna processing |
| WO1995030755A1 (fr) | 1994-05-10 | 1995-11-16 | Hisamitsu Pharmaceutical Co., Inc. | Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production |
| WO1995032300A1 (en) * | 1994-05-23 | 1995-11-30 | University Of Medicine & Dentistry Of New Jersey | Selective biological destruction of tumor cells |
| US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| WO1996028563A1 (en) | 1995-03-09 | 1996-09-19 | Bavarian Nordic | Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy |
| GB9510272D0 (en) * | 1995-05-22 | 1995-07-19 | Isis Innovation | Retroviral vectors |
| WO1997048277A1 (en) * | 1996-06-20 | 1997-12-24 | The Salk Institute For Biological Studies | Modular assembly retroviral vectors and uses thereof |
-
1996
- 1996-10-17 GB GBGB9621680.9A patent/GB9621680D0/en active Pending
-
1997
- 1997-10-17 PL PL97332876A patent/PL332876A1/xx unknown
- 1997-10-17 AU AU47123/97A patent/AU737801B2/en not_active Expired
- 1997-10-17 CN CNB971988838A patent/CN1195864C/zh not_active Expired - Lifetime
- 1997-10-17 JP JP10519087A patent/JP2001502903A/ja not_active Ceased
- 1997-10-17 EP EP97909437A patent/EP0939827B1/en not_active Expired - Lifetime
- 1997-10-17 IL IL12856497A patent/IL128564A0/xx unknown
- 1997-10-17 GB GB9903117A patent/GB2331522B/en not_active Expired - Lifetime
- 1997-10-17 CA CA002268271A patent/CA2268271A1/en not_active Abandoned
- 1997-10-17 CZ CZ991372A patent/CZ137299A3/cs unknown
- 1997-10-17 HU HU0000442A patent/HUP0000442A3/hu unknown
- 1997-10-17 NZ NZ334522A patent/NZ334522A/en not_active IP Right Cessation
- 1997-10-17 US US09/284,011 patent/US6235522B1/en not_active Expired - Lifetime
- 1997-10-17 WO PCT/GB1997/002858 patent/WO1998017816A1/en not_active Application Discontinuation
- 1997-10-17 KR KR1019990703355A patent/KR20000049250A/ko not_active Application Discontinuation
- 1997-10-17 AT AT97909437T patent/ATE520783T1/de not_active IP Right Cessation
-
1999
- 1999-04-13 NO NO991742A patent/NO991742L/no not_active Application Discontinuation
- 1999-04-14 BG BG103334A patent/BG103334A/xx unknown
- 1999-08-17 HK HK99103561A patent/HK1018481A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ137299A3 (cs) | 1999-07-14 |
| KR20000049250A (ko) | 2000-07-25 |
| CN1195864C (zh) | 2005-04-06 |
| HUP0000442A2 (hu) | 2000-06-28 |
| NZ334522A (en) | 2001-11-30 |
| GB2331522B (en) | 2001-05-23 |
| NO991742D0 (no) | 1999-04-13 |
| ATE520783T1 (de) | 2011-09-15 |
| CA2268271A1 (en) | 1998-04-30 |
| GB2331522A (en) | 1999-05-26 |
| US6235522B1 (en) | 2001-05-22 |
| JP2001502903A (ja) | 2001-03-06 |
| GB9903117D0 (en) | 1999-04-07 |
| EP0939827B1 (en) | 2011-08-17 |
| AU737801B2 (en) | 2001-08-30 |
| HUP0000442A3 (en) | 2001-09-28 |
| AU4712397A (en) | 1998-05-15 |
| GB9621680D0 (en) | 1996-12-11 |
| IL128564A0 (en) | 2000-01-31 |
| HK1018481A1 (en) | 1999-12-24 |
| PL332876A1 (en) | 1999-10-25 |
| CN1234075A (zh) | 1999-11-03 |
| EP0939827A1 (en) | 1999-09-08 |
| WO1998017816A1 (en) | 1998-04-30 |
| NO991742L (no) | 1999-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG103334A (en) | Antiviral vectors | |
| BG103397A (en) | Retroviral vectors | |
| GB9510272D0 (en) | Retroviral vectors | |
| MY119031A (en) | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses | |
| EP0702716A4 (en) | GENTHERAPY FOR HIV INFECTION AND AIDS WITH THE AID OF RIBOZYMS | |
| CA2011878A1 (en) | Immunogenic regions on the e7 protein of human papillomavirus type 16 | |
| CA2051288A1 (en) | Viral targeted destruction of neoplastic cells | |
| DK631688A (da) | 2',3'-dideoxy-2'-fluornucleosider, fremstillingen deraf samt praeparater indeholdende samme | |
| EP1262554A3 (en) | Defective packaging non-oncoviral vectors based on mpmv and hiv | |
| AU3258295A (en) | Retroviral vector hybrids and the use thereof for gene transfer | |
| EP0801575A4 (en) | RETROVIRAL VECTORS FOR EXPRESSION IN EMBRYONIC CELLS | |
| EP0736600A3 (en) | Use of an immunodeficiency suppressing virus which suppresses lymphokines (ISL) to prevent viral replicas, in particular those of retroviruses | |
| PT975783E (pt) | "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas" | |
| WO2000001835A3 (en) | Targeted integration into chromosomes using retroviral vectors | |
| DE3476784D1 (en) | Therapeutic compositions endowed with antiviral activity | |
| AU7289587A (en) | Immunosuppressive factor from human immunodeficiency virus (hiv) or hiv infected cells or cell lines, its use, corresponding antibodies and their use | |
| CA2141951A1 (en) | Inhibition of retrovirus infection | |
| WO1999034006A3 (en) | A method for the positive selection of cd4+ t-lymphocytes transduced with anti-hiv genes | |
| WO1995025806A3 (en) | Packaging-deficient lentiviruses | |
| AU4767093A (en) | Peptides derived from an immunosuppressive region in the retroviral genome | |
| CA2199131A1 (en) | Retroviral vector hybrids and the use thereof for gene transfer | |
| AU7052291A (en) | Genetic protection of animals against infection by the bovine leukemia virus, and provirus and recombinant virus derived from this virus | |
| ES2007741A6 (es) | Composiciones herbicidas a base de un herbicida de tipo glifosato y de un herbicida de tipo fenoxibenzoico, y procedimiento de tratamiento de vegetales indeseables por medio de estas composiciones. |